Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many reports of BIA-ALCL there have been in the UK; and which manufacturers of breast implants those reports have been associated with.

As has been previously shared in evidence submitted to the Women and Equalities Select Committee in July 2025, with further information in the document attached, the Medicines and Healthcare product Regulatory Agency (MHRA) closely monitors Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL), a cancer of the immune system, not a breast cancer, and publishes the output from this monitoring on the GOV.UK webpage, at the following link:

https://www.gov.uk/guidance/breast-implants-and-anaplastic-large-cell-lymphoma-alcl

The MHRA has developed, with advice from independent expert advisory group, a follow up strategy to collect further data on adverse incidents reporting BIA-ALCL. This has informed the information that is published on the MHRA webpage relating to BIA-ALCL which includes the most up to date number of confirmed reports of BIA-ALCL made to the MHRA, and the breakdown of the number of confirmed reports of primary BIA-ALCL cases by manufacturer of breast implant.

Please note that the data on the GOV.UK webpage should be interpreted in the context of the ‘Notes and limitations to the data’ section also provided on the webpage.